Table 1.
Descriptive Statistics of Study Cohort Characteristics
| SCD (n = 201) |
Control (n = 201) |
P value | |
|---|---|---|---|
| Age, years | 0.2590a | ||
| Median (SD) | 34 (14) | 35 (14) | |
| Minimum-Maximum | 18–80 | 18–81 | |
| Sex | 0.0179b | ||
| Female | 56.2% (n = 113) | 68.2% (n = 137) | |
| Male | 43.8% (n = 88) | 31.8% (n = 64) | |
| Race and Ethnicity | 0.0012b | ||
| Black or African American | 95.0% (n = 191) | 87.1% (n = 175) | |
| Hispanic | 2.0% (n = 4) | 9.5% (n = 19) | |
| Non-Black or African American, Non-Hispanic | 3.0% (n = 6) | 3.5% (n = 7) | |
| COVID vaccine type | 0.5963b | ||
| Pfizer-BioNTech | 78.6% (n = 158) | 80.6% (n = 162) | |
| Moderna | 19.4% (n = 39) | 16.9% (n = 34) | |
| Janssen (Johnson & Johnson) | 2.0% (n = 4) | 2.5% (n = 5) | |
| Number of vaccine dose Time since last dose, mean days (SD) | 0.6210b | ||
| 1 dose | 11.9% (n = 24) | 9.5% (n = 19) | |
| 254 days (96) | 225 days (135) | 0.9373a | |
| 2 dose | 50.7% (n = 102) | 52.7% (n = 106) | |
| 293 days (121) | 267 days (120) | 0.3793a | |
| 3 dose | 34.8% (n = 70) | 35.8% (n = 72) | |
| 154 days (81) | 108 days (103) | 0.0071a | |
| 4 dose | 2.5% (n = 5) | 2.0% (n = 4) | |
| 17 days (86) | 64 days (49) | 0.9762a |
a
Mann-Whitney test
b
Chi-square test